EMA Authorised: Perjeta (pertuzumab) — Roche Registration GmbH

View source ↗

Summary

European Medicines Agency authorises Perjeta (pertuzumab) for use in breast neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• Perjeta (pertuzumab)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Roche Registration GmbH. Decision date: 12/03/2026